HealthEquity (NASDAQ:HQY) Given New $94.00 Price Target at The Goldman Sachs Group

HealthEquity (NASDAQ:HQY) had its price objective trimmed by The Goldman Sachs Group from $107.00 to $94.00 in a report published on Thursday morning,Benzinga reports. The firm currently has a neutral rating on the stock.

A number of other brokerages have also issued reports on HQY. Mizuho assumed coverage on HealthEquity in a report on Wednesday, December 4th. They issued an “outperform” rating and a $126.00 price objective for the company. Wells Fargo & Company boosted their price target on HealthEquity from $110.00 to $125.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. JMP Securities raised their price target on HealthEquity from $105.00 to $107.00 and gave the company a “market outperform” rating in a report on Tuesday, December 10th. KeyCorp reduced their price objective on shares of HealthEquity from $120.00 to $110.00 and set an “overweight” rating for the company in a report on Monday. Finally, Barrington Research reissued an “outperform” rating and set a $112.00 target price on shares of HealthEquity in a research note on Friday, March 14th. One analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, HealthEquity currently has an average rating of “Buy” and a consensus price target of $112.23.

HealthEquity Trading Down 0.4 %

HealthEquity stock opened at $88.83 on Thursday. HealthEquity has a 52-week low of $65.01 and a 52-week high of $115.59. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $7.68 billion, a price-to-earnings ratio of 81.50, a PEG ratio of 1.60 and a beta of 0.62. The firm has a 50-day moving average price of $103.94 and a two-hundred day moving average price of $95.84.

Insider Buying and Selling

In other news, Director Robert W. Selander sold 5,750 shares of the company’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $111.29, for a total transaction of $639,917.50. Following the completion of the sale, the director now directly owns 78,219 shares of the company’s stock, valued at $8,704,992.51. This represents a 6.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 2.20% of the stock is currently owned by insiders.

Institutional Trading of HealthEquity

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Arcadia Investment Management Corp MI acquired a new stake in HealthEquity during the 4th quarter valued at $26,000. Transce3nd LLC acquired a new position in HealthEquity during the fourth quarter valued at $29,000. Smartleaf Asset Management LLC lifted its stake in HealthEquity by 34.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 384 shares of the company’s stock worth $37,000 after acquiring an additional 98 shares in the last quarter. Proficio Capital Partners LLC acquired a new stake in HealthEquity during the 4th quarter worth about $39,000. Finally, UMB Bank n.a. grew its stake in HealthEquity by 65.6% during the 4th quarter. UMB Bank n.a. now owns 414 shares of the company’s stock valued at $40,000 after acquiring an additional 164 shares in the last quarter. Institutional investors and hedge funds own 99.55% of the company’s stock.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.